Varespladib
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes. Varespladib acts by inhibiting secretory phospholipase A2 (sPLA2) and the drug is currently being evaluated in approximately 6500 patients with acute coronary syndromes receiving atorvastatin in the placebo-controlled VISTA 16 (NCT01130246) trial being conducted in North America and Europe. This review discusses the development history and scientific profile of this new compound.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varespladib (LY315920) is a repurposed inhibitor of snake venom PLA2 [83,84,85,86] and is one of the most advanced adjunct therapeutics under investigation.”
From Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities (2026) · cites this paper as [83]
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Snyder, D. W., Bach, N. J., Dillard, R. D., Draheim, S. E., Carlson, D. G., Fox, N. W., Roehm, N. W., Armstrong, C. T., Chang, C. H., Hartley, L. W., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38064-4 · Cited by 95
(2013) · Inflammation Research · doi:10.1007/11.1420-908x · Cited by 59
Richards, N. M. (1976) · Archives of Internal Medicine · doi:10.1001/archinte.1976.03630050101025 · Cited by 40
Research works printed but not linked: 2
- Parnham, 1996 Dec, Drug News and Perspective, 9, 631
- Kearney, 1999, Mediators of Inflammation, 8, 8
Cited by
Gutiérrez, J. M., Lewin, M. R., Williams, D. J., & Lomonte, B. (2020) · Toxins · doi:10.3390/toxins12020131 · Cited by 92
Snake Antivenom: Challenges and Alternate Approaches
Alangode, A., Rajan, K., & Nair, B. G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114135 · Cited by 88
Xie, C., Albulescu, L.-O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J. (2020) · Biomedicines · doi:10.3390/biomedicines8060165 · Cited by 58
Carter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., et al. (2022) · Toxins · doi:10.3390/toxins15010022 · Cited by 39
Alangode, A., Rajasekhar, A., Sabu, J. J., Krishna, S., Anuja, D., Sreeja, A., Remesh, G., Kaladevi, A., & Nair, B. G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156830
“Varespladib (LY315920) is a repurposed inhibitor of snake venom PLA 2 [83–86] and is one of the most advanced adjunct therapeutics under investigation.”
Metadata
- Authors
- &NA;
- Corresponding author
- &NA;
- Venue
- American Journal Cardiovascular Drugs
- Published
- 2011-04
- Volume
- 11
- Issue
- 2
- Pages
- 137-143
- ISSN
- 1175-3277 (ISSN-L)
- OpenAlex
- W4241977973
- Cited by
- 38
- References
- 4
- Citations by year
- 2026: 5 · 2024: 1 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 9 · 2019: 2 · 2018: 3 · 2016: 1 · 2015: 1
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- varespladib, acute coronary syndrome, oral dosage forms, atorvastatin, drug development history
- MeSH terms
- Acetates, Animals, Clinical Trials as Topic, Humans, Indoles, Keto Acids, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varespladib. https://app.cochat.ai/papers/10.2165/11533650-000000000-00000
- The paper
- &NA;. (2011). Varespladib. American Journal Cardiovascular Drugs. https://doi.org/10.2165/11533650-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.